Kliniske forsøg med Crohns sygdom: i kontrollererde kliniske forsøg var forhøjelse af ALAT sammenlignelig hos patienter, der modtog adalimumab eller placebo. ke
In all studies (I-VII), patients with raised ALT were asymptomatic and in most cases elevations were transient and resolved on continued treatment.